STAGE IV OVARIAN CANCER AJCC V8

This phase 2 study tests the drug pembrolizumab in 21 people with advanced solid tumors that have specific gene changes (BRCA1, BRCA2, POLE, or POLD1). The goal is to see if the drug can shrink or stop the cancer from growing. This is not a cure, but a way to control the disease.

This early-phase trial tests a combination of two drugs—niraparib and dostarlimab—in people with breast, pancreas, or ovarian cancers that have a BRCA gene mutation and have spread or can't be removed by surgery. Niraparib blocks a DNA repair process that cancer cells rely on, wh…

This early-phase study tests a new drug (BAY 1895344) combined with standard chemotherapy in people with advanced solid tumors, especially bladder cancer. The goal is to find the best dose and see if the combination is safe and tolerable. About 74 participants will receive the dr…

This early-phase trial tests the drug olaparib in 15 people with newly diagnosed BRCA-mutant ovarian, fallopian tube, or peritoneal cancer. Participants take olaparib for two cycles before their planned surgery to see if it can shrink tumors safely. The goal is to find out if thi…

This study tests an online program called Day by Day to help women with stage III or IV gynecologic cancer manage their fear of the cancer growing or coming back. About 23 women will try the program and report how useful it is and whether their anxiety improves. The goal is to se…

This study was designed to see if an online mental health program could help women with advanced gynecologic or breast cancer cope with the fear of their cancer coming back or getting worse. It planned to compare the program to standard educational materials. However, the study w…

This study looks at whether doctors can consistently measure the amount of paclitaxel (a chemotherapy drug) in the blood of cancer patients. The goal is to see if this information can help adjust doses to kill cancer while reducing nerve damage, a common side effect. About 22 adu…